Search Results - Clemons, M.
- Showing 1 - 1 results of 1
-
1
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer by Dent, R., Lindeman, G., Clemons, M., Wildiers, H., Chan, Arlene, McCarthy, N., Singer, C., Lowe, E., Watkins, C., Carmichael, J.
Published 2013Get full text